Univariable Analysis of Risk Factors for Proven/Probable Invasive Fungal Disease
| Variable . | Univariable Analysis . | |||
|---|---|---|---|---|
| HR . | Lower 95% CI . | Upper 95% CI . | P Value . | |
| Age | 1.085 | 1.034 | 1.138 | .001 |
| Antithymocyte globulin | 1.72 | .3181 | 9.3 | .529 |
| Cohort B (vs A) | 3.629 | .648 | 20.33 | .143 |
| Male sex (vs female) | 1.414 | .26 | 7.686 | .689 |
| Conditioning: RIC (vs MAT) | 1.041 | .1921 | 5.643 | .963 |
| Donor source (vs MRD) | ||||
| Unrelated donor | 1.135 | .2104 | 6.123 | .883 |
| Haploidentical | 0 | NA | NA | NA |
| Cord | 0 | NA | NA | NA |
| Mismatch (vs matched) | 0.63 | .0727 | 5.459 | .675 |
| Primary disease (vs lymphoma) | ||||
| AML/MDS | 1.533 | .1732 | 13.57 | .701 |
| ALL | 0 | NA | NA | NA |
| Other | 1.783 | .1125 | 28.27 | .6816 |
| Grade II–IV aGVHD (time dependent) | 1.164 | .1249 | 10.84 | .8942 |
| Variable . | Univariable Analysis . | |||
|---|---|---|---|---|
| HR . | Lower 95% CI . | Upper 95% CI . | P Value . | |
| Age | 1.085 | 1.034 | 1.138 | .001 |
| Antithymocyte globulin | 1.72 | .3181 | 9.3 | .529 |
| Cohort B (vs A) | 3.629 | .648 | 20.33 | .143 |
| Male sex (vs female) | 1.414 | .26 | 7.686 | .689 |
| Conditioning: RIC (vs MAT) | 1.041 | .1921 | 5.643 | .963 |
| Donor source (vs MRD) | ||||
| Unrelated donor | 1.135 | .2104 | 6.123 | .883 |
| Haploidentical | 0 | NA | NA | NA |
| Cord | 0 | NA | NA | NA |
| Mismatch (vs matched) | 0.63 | .0727 | 5.459 | .675 |
| Primary disease (vs lymphoma) | ||||
| AML/MDS | 1.533 | .1732 | 13.57 | .701 |
| ALL | 0 | NA | NA | NA |
| Other | 1.783 | .1125 | 28.27 | .6816 |
| Grade II–IV aGVHD (time dependent) | 1.164 | .1249 | 10.84 | .8942 |
Abbreviations: aGVHD, acute graft-vs-host disease; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CI, confidence interval; HR, hazard ratio; MAT, myeloablative conditioning; MDS, myelodysplastic syndrome; MRD, matched related donor; NA, not applicable; RIC, reduced intensity conditioning.
Univariable Analysis of Risk Factors for Proven/Probable Invasive Fungal Disease
| Variable . | Univariable Analysis . | |||
|---|---|---|---|---|
| HR . | Lower 95% CI . | Upper 95% CI . | P Value . | |
| Age | 1.085 | 1.034 | 1.138 | .001 |
| Antithymocyte globulin | 1.72 | .3181 | 9.3 | .529 |
| Cohort B (vs A) | 3.629 | .648 | 20.33 | .143 |
| Male sex (vs female) | 1.414 | .26 | 7.686 | .689 |
| Conditioning: RIC (vs MAT) | 1.041 | .1921 | 5.643 | .963 |
| Donor source (vs MRD) | ||||
| Unrelated donor | 1.135 | .2104 | 6.123 | .883 |
| Haploidentical | 0 | NA | NA | NA |
| Cord | 0 | NA | NA | NA |
| Mismatch (vs matched) | 0.63 | .0727 | 5.459 | .675 |
| Primary disease (vs lymphoma) | ||||
| AML/MDS | 1.533 | .1732 | 13.57 | .701 |
| ALL | 0 | NA | NA | NA |
| Other | 1.783 | .1125 | 28.27 | .6816 |
| Grade II–IV aGVHD (time dependent) | 1.164 | .1249 | 10.84 | .8942 |
| Variable . | Univariable Analysis . | |||
|---|---|---|---|---|
| HR . | Lower 95% CI . | Upper 95% CI . | P Value . | |
| Age | 1.085 | 1.034 | 1.138 | .001 |
| Antithymocyte globulin | 1.72 | .3181 | 9.3 | .529 |
| Cohort B (vs A) | 3.629 | .648 | 20.33 | .143 |
| Male sex (vs female) | 1.414 | .26 | 7.686 | .689 |
| Conditioning: RIC (vs MAT) | 1.041 | .1921 | 5.643 | .963 |
| Donor source (vs MRD) | ||||
| Unrelated donor | 1.135 | .2104 | 6.123 | .883 |
| Haploidentical | 0 | NA | NA | NA |
| Cord | 0 | NA | NA | NA |
| Mismatch (vs matched) | 0.63 | .0727 | 5.459 | .675 |
| Primary disease (vs lymphoma) | ||||
| AML/MDS | 1.533 | .1732 | 13.57 | .701 |
| ALL | 0 | NA | NA | NA |
| Other | 1.783 | .1125 | 28.27 | .6816 |
| Grade II–IV aGVHD (time dependent) | 1.164 | .1249 | 10.84 | .8942 |
Abbreviations: aGVHD, acute graft-vs-host disease; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CI, confidence interval; HR, hazard ratio; MAT, myeloablative conditioning; MDS, myelodysplastic syndrome; MRD, matched related donor; NA, not applicable; RIC, reduced intensity conditioning.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
